Clinical Laserthermia Systems AB (publ) announced that a new agreement has been signed with its supplier Image Guided Therapy SA (IGT). Under the terms of the agreement, CLS will acquire all rights to IGT's technology for MRI-based temperature measurement and control of laser-based tissue ablation. The agreement is an important part of the development of the company's technology platform and business strategy.

The agreement with IGT means that CLS now owns all rights to its product portfolio and can thus fully secure value creation in the continued work with product development and commercialization. The technology from IGT is currently used in the TRANBERG Thermal Therapy System with the Thermoguide Workstation, a product that is part of a clinical evaluation of the treatment of localized prostate cancer with focal therapy at Radboud University Medical Center in Nijmegen, the Netherlands. The technology is also used in ClearPoint Prism Neuro Laser Therapy System, a product that is in a limited market launch in the US with indications such as brain tumors and drug-resistant epilepsy and which is also included in a clinical study of MRI-guided laser ablation (NeuroLITT) of the tumor disease glioblastoma at Skåne University Hospital in Lund.